Health Trials

Clinical trials

4

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

CS-121 APOC3 Base Editing in Severe Hypertriglyceridemia

This is an open-label, single-arm, dose-escalation IIT clinical trial to evaluate the safety, tolerability, pharmacodynamics (PD), and pharmacokinetics (PK) of CS-121, an in vivo base editing therapy delivered by lipid nanoparticles targeting APOC3, in adult participants (18-65 years) with Severe Hypertriglyceridemia(sHTG).

Participants needed: 15
Trial details
Phase: Early Phase 1Age: 18-65Biological sex: AllType: InterventionalSponsor: CorrectSequence Therapeutics Co., LtdUpdated: Jun 18, 2026Locations: 1
Eligibility criteria

Male or female participants aged 18 years ≤ age < 65 years. [+4]

Currently participating in other interventional clinical studies, or having an i... [+18]

Read more
Status: Not yet recruiting

A Phase 2 Safety and Efficacy Study Evaluating CS-101 in Participants With β-Thalassemia Major

The goal of this open label, single-arm clinical study is to learn about the safety and efficacy of CS-101 in treating patients with β-Thalassemia Major

Participants needed: 20
Trial details
Phase: Phase 2Age: 12-35Biological sex: AllType: InterventionalSponsor: CorrectSequence Therapeutics Co., LtdUpdated: Mar 24, 2026Locations: 3
Eligibility criteria

Voluntarily signed informed consent. Male or female participants aged 12 to 35 y... [+4]

Received other investigational products or other experimental interventions with... [+18]

Read more
Status: Recruiting

CS-121 APOC3 Base Editing in FCS

This is an open-label, single-arm, dose-escalation Phase I clinical trial to evaluate the safety, tolerability, pharmacodynamics (PD), and pharmacokinetics (PK) of CS-121, an in vivo base editing therapy delivered by lipid nanoparticles targeting APOC3, in adult participants (18-55 years) with familial chylomicronemia syndrome (FCS).

Participants needed: 15
Trial details
Phase: Early Phase 1Age: 18-55Biological sex: AllType: InterventionalSponsor: CorrectSequence Therapeutics Co., LtdUpdated: Feb 11, 2026Locations: 1
Eligibility criteria

Male or female aged 18 to 55 years (inclusive) at the time of signing informed c... [+4]

Currently participating in another interventional clinical study, or last use of... [+9]

Read more
Status: Recruiting

CS-206 in Patients With Sickle Cell Disease

The goal of this open label, single-arm clinical study is to learn about the safety and efficacy of CS-101 injection in treating sickle cell disease.

Participants needed: 5
Trial details
Phase: Early Phase 1Age: 12-35Biological sex: AllType: InterventionalSponsor: CorrectSequence Therapeutics Co., LtdUpdated: Feb 10, 2026Locations: 1
Eligibility criteria

Participants must be between 12 to 35 years old (inclusive). Participants or the... [+14]

Female participants who are pregnant, breastfeeding, or planning pregnancy durin... [+10]

Read more